Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asacol 4.8 g/day in Active Ulcerative Colitis
NCT01059344Phase 3Completed
- Sponsor
- Tillotts Pharma AG
- Start
- Nov 2009
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in ulcerative colitis (UC) comparing Asacol 4.8g with Placebo (2 arms). Primary endpoint: Clinical Remission at 6 weeks. Started Nov 2009; status: completed.
02
Drugs
Salcrozine
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01059344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01059344.